Brightsurf Science News & Current Events

June 03, 2006
New drug extends lung cancer survival 22 percent, UC Davis Cancer Center researchers report
Adding the new molecularly targeted agent bortezomib to a standard chemotherapy regimen of gemcitabine and carboplatin prolonged survival in patients with advanced non-small cell lung cancer.

Gene therapy completely suppresses ovarian cancer growth in animal model
University of Pittsburgh School of Medicine researchers have used gene therapy to either completely abolish or significantly inhibit tumor progression in a mouse model of ovarian cancer.

Terminally ill patients continue to receive aggressive treatment at end of life
The increasing use of chemotherapy and intensive hospital treatment for cancer patients in their last two weeks of life continued at least into the late 1990s despite the growth of the hospice movement that emphasizes comforting personal bonds and controlling pain and discomfort, say researchers at the Dana-Farber Cancer Institute in Boston.

Age-related structural change may contribute to fracture risk
It is well established that post-menopausal women are at increased risk for developing osteoporosis, but could that be related to subtle pre-menopausal changes in bone structure?

Longest ever follow-up study of a targeted cancer therapy shows excellent results
The overall survival of most people with chronic myelogenous leukemia (CML) treated with imatinib (Gleevec, STI-571) is extremely high and the relapse rate is quite low, according to new data from a study out of the Oregon Health & Science University Cancer Institute.

OHSU Cancer Institute study points to future of personalized medicine
Targeted therapies that attack tumors at the molecular level are increasingly the treatment of choice for cancer patients.

Gene therapy protects mice from the effects of whole-body irradiation
University of Pittsburgh School of Medicine researchers have successfully protected mice against the damaging effects that radiation can have on bone marrow using gene therapy.

Osteoporisis treatment update
This week, at the International Osteoporosis Foundation's World Congress on Osteoporosis, in Toronto, Canada, researchers reported on some newer and some older treatments for osteoporosis.

Better survival seen for early breast cancer patients switched from tamoxifen to Aromasin
New data from the Intergroup Exemestane Study (IES) showed for the first time today that hormone sensitive postmenopausal early breast cancer patients who switched to Aromasin after 2 to 3 years of tamoxifen were 17% more likely to be alive and were 25% less likely to have their cancer return than patients who continued on tamoxifen for a full 5 years of therapy.

Female nursing home residents at lesser risk of osteoporotic fractures
New research presented at the IOF World Congress on Osteoporosis in Toronto, Canada suggests female nursing home residents have fewer skeletal fractures and are older when those fractures occur than are women who live at home.

Race and income converge to shape women's experiences with advanced breast cancer
Researchers at the University of Pittsburgh schools of Nursing and Medicine evaluated the impact of race and income on women's experiences with the disease and found much higher levels of symptom distress and lower levels of quality of life reported by low-income African-American women than women from other racial and economic groups.
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.